Heart failure drugs in the pipeline now number more than 100 and include familiar names plus dozens of new ones. Get a top-line look at 6 of the most promising.
Heart failure drugs in the pipeline now number more than 100 and reflect research ongoing at more than 100 pharmaceutical companies.
Spanning developmental stages, they include familiar agents such as omecamtiv mecarbil and investigational molecules, including a β3-adrenergic receptor antagonist and cardiac myotrope.
A report from market research company DelveInsitght, Heart Failure—Pipeline Insight, 2021, provides a comprehensive view of all the investigational agents. The full report must be purchased but we offer concise summaries of 6 novel therapeutic strategies that deserve attention.